skip to content
 

Seminars (DAEW03)

Videos and presentation materials from other INI events are also available.

Search seminar archive

Event When Speaker Title Presentation Material
DAEW03 15th August 2011
09:00 to 09:45
V Fedorov Design of clinical trials with multiple end points of different types
DAEW03 15th August 2011
09:45 to 10:30
A Grieve The Role of Operating Characteristic in Assessing Bayesian Designs in Pharmaceutical Drug Development
DAEW03 15th August 2011
11:00 to 11:45
D Berry The Critical Path: "Biomarker Development and Streamlining Clinical Trials"
DAEW03 15th August 2011
11:45 to 12:30
A Atkinson Experiments for Enzyme Kinetic Models
DAEW03 15th August 2011
14:00 to 14:45
A Donner The Role of Cluster Randomization Trials in Health Research
DAEW03 15th August 2011
14:00 to 14:45
J Lee Biomarker-based Bayesian Adaptive Designs for Targeted Agent Development - Implementation and Lessons Learned from the BATTLE Trial
DAEW03 15th August 2011
14:45 to 15:25
M Campbell Cluster Randomised Trials: coping with selective recruitment, baseline covariates and anticipated drop-outs?
DAEW03 15th August 2011
14:45 to 15:25
K Wathen ISPY-2: Adaptive Design to Identify Treatments for Biomarker
DAEW03 15th August 2011
15:25 to 16:05
S Eldridge Sample size calculations for cluster randomised trials
DAEW03 15th August 2011
15:25 to 16:05
T Braun Bayesian Adaptive Designs for Identifying Maximum Tolerated Combinations of Two Agents
DAEW03 15th August 2011
16:35 to 17:15
I White A cluster-randomised cross-over trial
DAEW03 15th August 2011
16:35 to 17:15
B Bogachka Dose Selection Incorporating PK/PD Information in Early Phase Clinical Trials.
DAEW03 15th August 2011
17:15 to 17:55
C Weijer Ethical issues posed by cluster randomized trials in health research
DAEW03 15th August 2011
17:15 to 17:55
K Cheung Objective Calibration of the Bayesian Continual Reassessment Method
DAEW03 16th August 2011
09:30 to 10:00
V Dragalin Adaptive Dose-Ranging Designs with Two Efficacy Endpoints
DAEW03 16th August 2011
10:00 to 10:30
L Pronzato Penalized optimal design for dose finding
DAEW03 16th August 2011
10:30 to 11:00
C Jennison Jointly optimal design of Phase II and Phase III clinical trials: an over-arching approach
DAEW03 16th August 2011
11:30 to 12:00
S-J Wang Utility and pitfals of dose ranging trials with multiple study objectives: fixed or adaptive
DAEW03 16th August 2011
12:00 to 12:30
J Pinheiro Improving dose-finding methods in clinical development: design, adaptation, and modeling
DAEW03 16th August 2011
14:00 to 14:30
F Bretz Response-adaptive dose-finding under model uncertainty
DAEW03 16th August 2011
14:30 to 15:00
H Thygesen Dose Escalation using a Bayesian Model: rational decision rules.
DAEW03 16th August 2011
15:00 to 15:30
B Neuenschwander Bayesian approaches to Phase I clinical trials: methodological and practical aspects
DAEW03 16th August 2011
15:30 to 16:00
S Leonov Application of model-based designs in drug development
DAEW03 16th August 2011
16:45 to 18:00
M Krams Design of Experiments in Healthcare, dose-ranging studies, astrophysics and other dangerous things
DAEW03 17th August 2011
09:00 to 09:45
J Louviere A Brief History of DCEs and Several Important Challenge
DAEW03 17th August 2011
09:45 to 10:30
M Ryan Discrete Choice Experiments in Health Economics
DAEW03 17th August 2011
11:00 to 11:45
J Rose Sample size, statistical power and discrete choice experiments: How much is enough
DAEW03 17th August 2011
11:00 to 11:45
C Taylor Systematic review of the use of stepped wedge cluster randomized trials
DAEW03 17th August 2011
11:45 to 12:30
P Goos Optimal designs for discrete choice experiments in the presence of many attributes
DAEW03 17th August 2011
11:45 to 12:30
L Moulton Challenges in the Design and Analysis of a Randomized, Phased Implementation (Stepped-Wedge) Study in Brazil
DAEW03 17th August 2011
12:30 to 13:00
SG Thompson Stepped wedge randomised trials
DAEW03 17th August 2011
12:30 to 13:00
H Grossmann Partial profile paired comparison designs for avoiding information overload
DAEW03 18th August 2011
09:00 to 09:45
E Lancsar Discrete choice experimental design for alternative specific choice models: an application exploring preferences for drinking water
DAEW03 18th August 2011
09:45 to 10:30
R Kessels The usefulness of Bayesian optimal designs for discrete choice experiments
DAEW03 18th August 2011
11:45 to 12:30
P van de Ven An efficient alternative to the complete matched-pairs design for assessing non-inferiority of a new diagnostic test
DAEW03 18th August 2011
14:00 to 14:45
Y Ji From Bench to Bedside: The Application of Differential Protein Networks on Bayesian Adaptive Designs for Trials with Targetted Therapies
DAEW03 18th August 2011
14:45 to 15:30
K Kim A Bayesian Adaptive Design with Biomarkers for Targeted Therapies and Some Commentary on Adaptive Designs
DAEW03 18th August 2011
16:00 to 16:45
P Thall Optimizing the Concentration and Bolus of a Drug Delivered by Continuous Infusion
DAEW03 18th August 2011
16:45 to 17:30
B Mukherjee Discussion of three talks on (covariate) adaptive designs
DAEW03 19th August 2011
09:45 to 10:30
B Bornkamp Functional uniform prior distributions for nonlinear regression
DAEW03 19th August 2011
11:00 to 11:45
M Savelieva Praz PKPD modelling to optimize dose-escalation trials in Oncology
DAEW03 19th August 2011
11:45 to 12:30
J Taylor Designs and models for Phase I oncology trials with intra-patient dose escalation
DAEW03 19th August 2011
14:00 to 14:45
N Flournoy Some Issues Response-Adaptive Designs for Dose-finding Experiments
DAEW03 19th August 2011
14:45 to 15:30
B Rosenberger Principles for Response-Adaptive Randomization
DAEW03 19th August 2011
15:30 to 16:15
A Giovagnoli Recent developments in adaptive clinical trials to account for individual and collective ethics
University of Cambridge Research Councils UK
    Clay Mathematics Institute London Mathematical Society NM Rothschild and Sons